Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
Anno:
2022
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Formato:
Elettronico
Referee:
No
Nome rivista:
ELIFE
ISSN Rivista:
2050-084X
N° Volume:
11
Intervallo pagine:
1-17
Parole chiave:
Omicron; bamlanivimab/etesevimab; casirivimab/imdevimab; early covid-19; human; medicine; monoclonal antibody; sotrovimab
Breve descrizione dei contenuti:
Recent in-vitro data have shown that the activity of monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies according to the variant of concern (VOC). No studies have compared the clinical efficacy of different mAbs against Omicron VOC.